Introduction {#sec1}
============

Cervical cancer is the third most common cancer amongst women worldwide, with 527,624 new cases and 265,672 deaths in 2012 \[[@B1]\]. It is estimated that by 2020, there will be 609,270 new cases and 317,727 deaths worldwide \[[@B2]\]. While cancer-related mortality has decreased with the implementation of screening programs worldwide, incidence is on the rise in developing countries, where about 80% of cases occur \[[@B3]\]. China is a multiethnic country, the incidence of cervical cancer in all ethnic groups is different, and of which Xinjiang Uygur population incidence is the highest. In recent years, much attention has been paid to the study of cervical cancer in Uygur women \[[@B4]\]. However, the pathogenesis of cervical cancer was not fully understood. Etiological studies have shown that cervical cancer is the result of a combination of factors, including the high-risk human papillomavirus (HPV) infection, environmental, behavioral, and genetic factors \[[@B5],[@B6]\]. In recent years, increasing evidence has emphasized the role of genetic factors in the pathogenesis of cervical cancer. Studies based on single nucleotide polymorphisms (SNPs) and genome-wide association studies have confirmed the relationship between genetic variations and the risk of cervical cancer in differen*P-*t populations \[[@B7]\].

Tumor necrosis factor (TNF)-α- induced protein 8 (TNFAIP8) is a recently identified protein family reported to have important roles in immunity, inflammation, and tumorigenesis. TNFAIP8L1 is a member of the TNFAIP8 family \[[@B10]\]. Past studies have shown a strong correlation between TNFAIP8 protein and the development of a lvariety of cancers, including gynecological cancers such as breast cancer, cervical cancer, ovarian cancer, and endometrial cancer \[[@B11]\]. In addition, the regulation of these proteins has been found to promote basic characteristics of cancer, such as tumor growth, proliferation, inhibition of apoptosis, and angiogenesis \[[@B12]\]. However, the exact function of *TNFAIP8L1* in cervical cancer is unknown. The *FLT1* gene encodes VEGFR1, a member of the vascular endothelial growth factor receptor (VEGFR) family. The VEGF system is crucial for angiogenesis, which is considered to be the key to the occurrence of malignant tumors \[[@B13],[@B14]\]. A previous study showed that *VEGF* is an important regulator of endometrial tumor angiogenesis, and *FLT1* is a great marker of vascular proliferation \[[@B15],[@B16]\]. At present, the function of *FLT1* in cervical cancer has not been deeply studied.

In this case-control study, we investigated the association between SNPs of *TNFAIP8L1* and *FLT1* genes and cervical cancer risk amongst Xinjiang Uygur females.

Materials and methods {#sec2}
=====================

Study population {#sec2-1}
----------------

A total of 342 patients were recruited from the People's Hospital of Xinjiang Uygur Autonomous Region as preliminary samples. All patients were pathologically confirmed with cervical cancer by at least two pathologists. The International Federation of Gynecology and Obstetrics (FIGO) stage was also recorded for further analysis. Notably, patients who received systemic or topical treatment were excluded from our study. In addition, women eligible for age and ethnicity were recruited continuously from the same hospital health screening center as a control group. Finally, the study included 498 healthy individuals with no history of gynecologic disease or tumors. All participants were from Xinjiang Uygur ethnic group.

DNA genotyping {#sec2-2}
--------------

The total DNA isolation was performed from the peripheral blood samples provided by the experimental subjects using the GoldMag DNA Purification Kit (GoldMag Co. Ltd, Xi'an City, China). The concentration and quality of the purified DNA were measured with Nanodrop 2000 UV spectrophotometer (Thermo Scientific, Waltham, MA, U.S.A.). Screening the polymorphisms with minor allele frequency (MAF) more than 5% in the 1000 genomes database (<http://www.internationalgenome.org/>) and the dbSNP database (<https://www.ncbi.nlm.nih.gov/projects/SNP/>). We eventually selected five SNPs including rs9917028, rs10426502, and rs1060555 of *TNFAIP8L1* and rs9513111 and rs677471 of *FLT1* for further genotype identification and risk association analysis. The Agena Bioscience Assay Design Suite software, version 2.0 (<https://agenacx.com/online-tools/>) was applied for MassARRAY assay design. The SNP genotype was identified by the MassARRAY Nanodispenser and MassARRAY iPLEX method (Agena Bioscience, San Diego, CA, U.S.A.) according to the manufacturer's instructions. Data management and presentation were conducted by the Agena Bioscience TYPER software, version 4.0 \[[@B17]\].

Statistical analysis {#sec2-3}
--------------------

All the basic statistical analyses were carried out using SPSS 20.0 (SPSS, Chicago, IL, U.S.A.) and Microsoft Excel. Age distribution differences between cases and healthy controls were analyzed by the independent sample *t*-test. The departure from Hardy-Weinberg equilibrium (HWE) was determined by comparing the observed and expected heterozygosity on controls with the Chi-square test. Statistical significance was defined as *P*-value less than 0.05. All *P*-values were two tailed. Furthermore, the association study was performed in multiple inheritance models (co-dominant, dominant, recessive, and additive) using SNPstats software (<http://bioinfo.iconcologia.net/SNPstats>). Odds ratio (ORs) values and 95% CIs were calculated using an age-adjusted logistic regression to assess the risk of cervical cancer. Haploview 4.2 software (Cambridge, MA, U.S.A.) was used to determine the pairwise linkage disequilibrium (LD), using the standardized D′ and r^2^ values. The false-positive report probability (FPRP) was calculated to evaluate the significant results using the SAS software 9.4 (SAS Institute, Cary, N.C., U.S.A.). We set 0.2 as the FPRP threshold to detect an OR of 0.67/1.50 (protective/risk effect) associated with genotype and haplotype in the study. The FPRP value of less than 0.2 was considered a significant finding \[[@B20],[@B21]\].

Results {#sec3}
=======

Characteristics of the study subjects {#sec3-1}
-------------------------------------

In the present study, the age distribution was matched between the case group and the control group (*P*\>0.05). A total of 342 cervical cancer patients and 498 healthy subjects were included, with the average age of 43.46 and 43.27, respectively ([Table 1](#T1){ref-type="table"}). Moreover, the frequency distribution of the cervical cancer patients regarding FIGO stage and HPV status were calculated and listed in [Table 1](#T1){ref-type="table"}.

###### Characteristics of the study population

  Variable                Cases           Controls        *P*-value
  ----------------------- --------------- --------------- -----------
  **Age (mean ± S.D.)**   43.46 ± 13.03   43.27 ± 11.78   0.829
  ≤43                     166 (49%)       235 (53%)       
  \>43                    176 (51%)       263 (47%)       
  **Stage**                                               
  I--II                   132 (39%)                       
  III--IV                 80 (23%)                        
  Absent                  130 (38%)                       
  **HPV status**                                          
  Negative                51 (15%)                        
  Positive                195 (57%)                       
  Absent                  96 (28%)                        
  **Total**               342             498             

*P*-value obtained from independent sample *t*-test.

Basic information for the candidate SNPs {#sec3-2}
----------------------------------------

Basic information and preliminary statistical results of the selected SNPs are showed in [Table 2](#T2){ref-type="table"}. HWE *P*-values were obtained with Chi-square tests and all SNPs (rs9917028, rs10426502, rs1060555, rs9513111, and rs677471) were in HWE (*P*\>0.05). The values of the MAF were higher than 5%.

###### Basic information regarding candidate SNPs

  SNP          Chromosome   Position   Alleles   Gene          Role     MAF     HWE     OR      *P-*value              
  ------------ ------------ ---------- --------- ------------- -------- ------- ------- ------- ---------------------- -----------
  rs9917028    Chr19        4640971    G/A       *TNFAIP8L1*   Intron   0.330   0.382   0.107   **0.80 (0.65-0.98)**   **0.032**
  rs10426502   Chr19        4651257    G/A       *TNFAIP8L1*   Intron   0.037   0.067   0.154   **0.53 (0.33-0.84)**   **0.007**
  rs1060555    Chr19        4652810    C/G       *TNFAIP8L1*   3′UTR    0.238   0.287   0.154   **0.78 (0.62-0.97)**   **0.026**
  rs9513111    Chr13        28423426   C/T       *FLT1*        Intron   0.326   0.674   0.766   0.91 (0.74--1.12)      0.385
  rs677471     Chr13        28489675   C/T       *FLT1*        Intron   0.355   0.645   0.160   1.08 (0.88--1.33)      0.448

*P-*values were calculated with Chi-square tests. *P\<*0.05 indicates statistical significance.

SNPs and cervical cancer risk {#sec3-3}
-----------------------------

The differences in allele frequency between cases and controls were compared by χ^2^ test ([Table 2](#T2){ref-type="table"}). The allele with lower frequency of each SNP was regarded as a risk factor. The results indicated that alleles rs9917028-A (*P=*0.032), rs10426502-A (*P=*0.007), and rs1060555-G (*P=*0.026) of *TNFAIP8L1* were risk alleles for cervical cancer amongst Xinjiang Uygur female.

As showed in [Table 3](#T3){ref-type="table"}, significant associations were existed between *TNFAIP8L1* rs9917028, and decreased risk of cervical cancer in allele model, co-dominant model, and additive model (allele model: OR = 0.80, 95% CI: 0.65--0.98, *P=*0.032; co-dominant model: OR = 0.64, 95% CI: 0.42--0.99, *P=*0.044; additive model: OR = 0.81, 95% CI: 0.66--0.99, *P=*0.039). *TNFAIP8L1* rs10426502 and rs1060555 were decreased risk of cervical cancer in allele model, co-dominant model, dominant model, and additive model (rs10426502: allele model: OR = 0.53, 95% CI: 0.33--0.84, *P=*0.007; co-dominant model: OR = 0.47, 95% CI: 0.28--0.76, *P=*0.003; dominant model: OR = 0.49, 95% CI: 0.30--0.79, *P=*0.004; additive model: OR = 0.52, 95% CI: 0.32--0.83, *P=*0.007. rs1060555: allele model: OR = 0.78, 95% CI: 0.62--0.97, *P=*0.026; co-dominant model: OR = 0.70, 95% CI: 0.52--0.93, *P=*0.015; dominant model: OR = 0.70, 95% CI: 0.53--0.93, *P=*0.012; additive model: OR = 0.77, 95% CI: 0.61--0.97, *P=*0.024).

###### The relationship between *TNFAIP8L1* gene polymorphism and cervical cancer

  SNP          Model         Genotype   Case           Control      Adjusted by age         
  ------------ ------------- ---------- -------------- ------------ ----------------------- -----------
  rs9917028    Co-dominant   GG         157 (46%)      199 (40%)    1                       
                             GA         144 (42%)      218 (44%)    0.84 (0.62--1.13)       0.241
                             AA         41 (12%)       81 (16%)     **0.64 (0.42--0.99)**   **0.044**
               Dominant      GG         157 (46%)      199 (40%)    1                       
                             GA--AA     185 (54%)      299 (60%)    0.78 (0.59--1.04)       0.088
               Recessive     GG-GA      301 (88%)      417 (84%)    1                       
                             AA         41 (12%)       81 (16%)     0.70 (0.47--1.05)       0.087
               Additive      ---        ---            ---          **0.81 (0.66--0.99)**   **0.039**
  rs10426502   Co-dominant   GG         317 (93%)      431 (83%)    1                       
                             GA         23 (6%)        67 (17%)     **0.47 (0.28--0.76)**   **0.003**
                             AA         1 (1%)         0 (0%)       ---                     0.999
               Dominant      GG         317 (93%)      431 (83%)    1                       
                             GA-AA      24 (7%)        67 (17%)     **0.49 (0.30--0.79)**   **0.004**
               Recessive     GG-GA      341 (91.90%)   498 (100%)   1                       
                             AA         1 (1%)         0 (0%)       ---                     0.999
               Additive      ---        ---            ---          **0.52 (0.32--0.83)**   **0.007**
  rs1060555    Co-dominant   CC         199 (58%)      246 (49%)    1                       
                             CG         123 (36%)      218 (44%)    **0.70 (0.52--0.93)**   **0.015**
                             GG         20 (6%)        34 (7%)      0.73 (0.41--1.30)       0.285
               Dominant      CC         199 (58%)      246 (49%)    1                       
                             CG-GG      143 (42%)      252 (57%)    **0.70 (0.53--0.93)**   **0.012**
               Recessive     CC-CG      322 (94%)      464 (93%)    1                       
                             GG         20 (6%)        34 (7%)      0.85 (0.48--1.50)       0.571
               Additive      ---        ---            ---          **0.77 (0.61--0.97)**   **0.024**

*P-*values were calculated with wald-test. *P\<*0.05 indicates statistical significance.

Based on age stratification, we tried to determine the effect of these variants on the risk of cervical cancer, as showed in [Table 4](#T4){ref-type="table"}. In accordance with our statistically significant findings of the allele model, the minor allele of rs10426502, and rs1060555 in *TNFAIP8L1* played roles in reducing the risk of cervical cancer in Uygur women over 43 years old (rs10426502: OR = 0.44, 95% CI: 0.22--0.88, *P=*0.017; rs1060555: OR = 0.72, 95% CI: 0.53--0.97, *P=*0.033). Amongst Uygur women under 43 years of age, the rs9917028-'AA' genotype of *TNFAIP8L1* reduced the risk of cervical cancer in genotype model and additive model (genotype model: OR = 0.45, 95% CI: 0.22--0.91, *P=*0.026; additive model: OR = 0.47, 95% CI: 0.24--0.91, *P=*0.025). Amongst Uygur women over 43 years of age, individuals carrying the heterozygous genotype rs1060555-'CG' in *TNFAIP8L1* (OR = 0.40, 95% CI: 0.17--0.92, *P=*0.017) were less likely to suffer from cervical cancer when compared with the homozygous 'CC'. In addition, rs10426502 and rs1060555 of *TNFAIP8L1* were significantly associated with reduced risk of cervical cancer in the dominant and additive models, as well as rs9513111 of *FLT1* was significantly associated with reduced risk of cervical cancer in the recessive model (*P*\<0.05).

###### Relationships between *TNFAIP8L1* and *FLT1* polymorphism and cervical cancer risk according to the stratification by age

  SNP           Model       Genotype   ≤43                     \>43                                
  ------------- ----------- ---------- ----------------------- ----------- ----------------------- -----------
  rs9917028     Allele      G          1                                   1                       
  *TNFAIP8L1*               A          0.75 (0.56--1.02)       0.064       0.84 (0.64--1.12)       0.238
                Genotype    GG         1                                   1                       
                            GA         0.94 (0.61--1.43)       0.766       0.75 (0.50--1.15)       0.187
                            AA         **0.45 (0.22--0.91)**   **0.026**   0.80 (0.46--1.40)       0.434
                Dominant    GG         1                                   1                       
                            GA-AA      0.81 (0.54--1.21)       0.305       0.77 (0.52--1.13)       0.180
                Recessive   GG-GA      1                                   1                       
                            AA         **0.47 (0.24--0.91)**   **0.025**   0.92 (0.55--1.55)       0.757
                Additive    ---        0.75 (0.56--1.02)       0.065       0.86 (0.66--1.13)       0.281
  rs10426502    Allele      G          1                                   1                       
  *TNFAIP8L1*               A          0.62 (0.33--1.19)       0.149       **0.44 (0.22--0.88)**   **0.017**
                Genotype    GG         1                                   1                       
                            GA         0.53 (0.26--1.07)       0.077       ---                     ---
                            AA         ---                     0.999       ---                     ---
                Dominant    GG         1                                   1                       
                            GA-AA      0.57 (0.29--1.14)       0.112       **0.42 (0.21--0.86)**   **0.017**
                Recessive   GG-GA      1                                   1                       
                            AA         ---                     0.999       ---                     ---
                Additive    ---        0.63 (0.33--1.22)       0.173       **0.42 (0.21--0.86)**   **0.017**
  rs1060555     Allele      C          1                                   1                       
  *TNFAIP8L1*               G          0.86 (0.62--1.19)       0.355       **0.72 (0.53--0.97)**   **0.033**
                Genotype    CC         1                                   1                       
                            CG         0.94 (0.62--1.42)       0.760       **0.54 (0.36--0.82)**   **0.003**
                            GG         0.59 (0.22--1.60)       0.303       0.79 (0.38--1.64)       0.527
                Dominant    CC         1                                   1                       
                            CG-GG      0.89 (0.60--1.34)       0.583       **0.58 (0.39--0.85)**   **0.005**
                Recessive   CC-CG      1                                   1                       
                            GG         0.61 (0.23--1.62)       0.321       1.03 (0.50--2.10)       0.935
                Additive    ---        0.87 (0.61--1.22)       0.406       **0.71 (0.52--0.97)**   **0.030**
  rs9513111     Allele      T          1                                   1                       
  *FLT1*                    C          1.05 (0.78--1.41)       0.773       0.81 (0.61--1.08)       0.144
                Genotype    TT         1                                   1                       
                            TC         0.89 (0.58--1.36)       0.581       1.02 (0.68--1.54)       0.913
                            CC         1.38 (0.69--2.76)       0.359       0.55 (0.29--1.04)       0.067
                Dominant    TT         1                                   1                       
                            TC-CC      0.96 (0.64--1.44)       0.852       0.89 (0.61--1.31)       0.561
                Recessive   TT-TC      1                                   1                       
                            CC         1.47 (0.76--2.83)       0.250       **0.54 (0.29--0.99)**   **0.049**
                Additive    ---        1.06 (0.78--1.45)       0.695       0.82 (0.62--1.09)       0.166

*P-*values were calculated with wald-test. *P*\<0.05 indicates statistical significance.

Haplotype analyses and false-positive report {#sec3-4}
--------------------------------------------

Furthermore, haplotype analyses were performed and a LD block was found in the *TNFAIP8L1* gene, formed by rs10426502-rs1060555 ([Figure 1](#F1){ref-type="fig"}). The haplotypes AG (OR = 1.94, 95% CI: 0.20--3.13, *P=*0.007) and GC (OR = 1.30, 95% CI: 1.03--1.63, *P=*0.026) were significantly associated with an increased risk for cervical cancer in Uyghur population ([Table 5](#T5){ref-type="table"}).

![LD block construction\
Block rs10426502-rs1060555 was detected in *TNFAIP8L1*. (D′ = 1.0, r^2^ = 0.159).](bsr-39-bsr20191155-g1){#F1}

###### Haplotype frequencies of *TNFAIP8L1* SNPs and the association with cervical cancer risk

  Gene          Haplotype               Haplotype frequency   OR (95% CI)   *P-*value               
  ------------- ----------------------- --------------------- ------------- ----------------------- -----------
                rs10426502\|rs1060555                                                               
  *TNFAIP8L1*   \_AG\_                  0.9633                0.933         **1.94 (1.20--3.13)**   **0.007**
                \_GG\_                  0.7977                0.780         1.11 (0.87--1.42)       0.386
                \_GC\_                  0.761                 0.713         **1.30 (1.03--1.63)**   **0.026**

*P-*values were calculated with Pearson's Chi-square tests. *P\<*0.05 indicates statistical significance.

FPRP values at different prior probability levels were calculated to evaluate significance results (Supplementary Table S1). For a prior probability of 0.1, the FPRP values were less than 0.2 for the associations of rs10426502, rs1060555 alleles, and genotypes with decreased risk of cervical cancer (rs10426502: allele-A: 0.094; GA: 0.045; GA-AA: 0.062. rs1060555: allele-G: 0.187 CG: 0.112; CG-GG: 0.112). And the FPRP values were also less than 0.2 for the associations of haplotypes with increased risk of cervical cancer (rs10426502\|rs1060555: AG: 0.098; GC: 0.172). In contrast, we observed greater FPRP values for the significant associations between rs9917028 and cervical cancer risk, suggesting some possible bias in the findings due to limited sample size, which need further validation in larger sample.

Discussion {#sec4}
==========

In the present study, selected SNPs in *TNFAIP8L1* and *FLT1* and their association with cervical cancer risk were investigated for the first time. Three *TNFAIP8L1* variants and one variant of *FLT1* were associated with reduced cervical cancer susceptibility amongst females from Xinjiang Uyghur Autonomous Region of China.

*TNFAIP8L1* plays an important role in malignant tumor. Immunohistochemistry and western blot analysis showed that TNFAIP8L1-specific antibodies were expressed in both male and female reproductive organs and germ cell tissues of mice. In addition, elevated *TNFAIP8L1* mRNA levels were detected in human gynecological cancer cells, including cervical and ovarian cancer cells \[[@B22]\]. As a regulator of cell death, *TNFAIP8L1* plays an indispensable role in tumor cell necrosis. Studies have shown that *TNFAIP8L1* can induce hepatocellular carcinoma cell apoptosis by interacting with Rac1 \[[@B23],[@B24]\]. In support of this view, *TNFAIP8L1* expression was down-regulated in hepatocellular carcinoma tissues compared with adjacent normal tissues. In addition, *TNFAIP8L1* was found to significantly reduce tumor burden *in vivo* and cell proliferation *in vitro*. Similar to hepatocellular carcinoma, down-regulation of *TNFAIP8L1* has also been observed in lung cancer \[[@B12]\]. Our study showed that these three candidate SNPs (rs9917028, rs10426502, and rs1060555) were risk factors for cervical cancer amongst Uygur women in Xinjiang. We hypothesized that these three SNPs might affect the expression and function of *TNFAIP8L1* in the development of cervical cancer.

The development and metastasis of primary tumors require angiogenesis, growth, movement, and detachment. Therefore, angiogenesis, the formation of blood vessels, has been identified as the key to the occurrence and development of malignant tumors. VEGF is considered as an important regulator of angiogenesis \[[@B15],[@B25]\]. VEGF receptor 1 (FLT1) is one of the targets of VEGF, which can regulate the growth and migration of endothelial cells and regulate angiogenesis. Recent studies have shown that FLT1 present and functional in different human cancer cells, and VEGF activation of FLT1 can be involved in the process of tumor progression \[[@B26]\]. *FLT1* has been shown to be a marker of angiogenesis in endometrial cancer, but its function as a predictor has not been determined. Daniel et al. believed that the *FLT1*-snp allele might be an important risk factor for angiogenesis-related disease \[[@B15]\]. Currently, VEGFA and its receptor-FLT1, as pro-angiogenic growth factor, are related to the promotion of angiogenesis, vascular permeability, cell migration and gene expression, and have become the targets of anticancer treatment \[[@B29]\]. Our findings suggest that *FLT1* rs9513111 may serve as a clinical predictor in Uygur women over 43 years of age. Our experimental results should be further verified in a larger sample size

There are still some limitations in the present study. First, this work detected the effect of SNP of two genes on cervical cancer susceptibility, and the specific molecular mechanism needs to be further explored. Second, lack of other clinical information. Therefore, further studies with a larger sample size and functional experiments are required.

Our study validated the relationship between *TNFAIP8L1* and *FLT1* variations and the risk of cervical cancer in Uygur women. These SNPs (rs9917028, rs10426502, rs1060555, and rs9513111) are expected to be new targets for early diagnosis and prevention of cervical cancer in Uygur women.
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